Premier Biotech Acquires NexScreen and TransMed

Premier Biotech Acquires NexScreen and TransMed

June 19, 2026

Healthcare Services

Premier Biotech (backed by Align Capital Partners) announced the acquisitions of NexScreen and TransMed to expand its drug and alcohol testing diagnostic product portfolio and global footprint. The deals add NexScreen’s point-of-care diagnostic testing presence in Australia and New Zealand and TransMed’s drug testing product catalog, e-commerce platform, and direct customer base.

Premier Biotech Acquires GH Solutions to Expand Point-of-Care Testing Presence

April 9, 2026

Healthcare Services

Align Capital Partners-backed Premier Biotech has acquired GH Solutions, a distributor of point-of-care diagnostic testing products. The deal expands Premier’s customer base and broadens the solutions GH can offer to Premier’s existing network, with focus on government and workplace customers.

Premier Biotech Acquires National Test Systems

November 5, 2025

Medical Devices

Premier Biotech, a portfolio company of Align Capital Partners, has acquired National Test Systems (NTS), a provider of rapid point-of-care drug screening supplies and services that serves more than 1,500 facilities across the United States. The acquisition expands Premier's point-of-care testing capabilities (including oral fluid testing) and deepens its presence in government and behavioral health end markets; NTS CEO Andrew Panico will remain involved to support the transition.

Premier Biotech (ACP) Acquires OraSure Toxicology Line and Green Earth Biomedical's Mexican Subsidiary (GEM)

April 10, 2025

Medical Devices

Premier Biotech, a portfolio company of Align Capital Partners, acquired certain assets comprising OraSure Technologies' substance abuse testing business line and the Mexican subsidiary of Green Earth Biomedical LLC (GEM). The transactions expand Premier's oral-fluid toxicology product portfolio and accelerate its international distribution footprint in Mexico and Latin America.

ScreenPoint Medical Acquires Biomediq A/S

January 8, 2025

Medical Devices

ScreenPoint Medical has acquired Biomediq A/S to integrate Biomediq's quantitative imaging biomarkers and mammographic texture-risk model into ScreenPoint's Transpara breast-AI platform. The acquisition brings automated 2D/3D mammogram risk-analysis capabilities and the lead author of a related Radiology study, Andreas D. Lauritzen, will join ScreenPoint to accelerate development.

Align Capital Partners Recapitalizes Premier Biotech

December 7, 2022

Medical Devices

Align Capital Partners has completed a recapitalization of Premier Biotech, a Minneapolis-based provider of point-of-care drugs of abuse testing devices and accredited laboratory services. Cascadia Capital served as exclusive financial advisor; Align will partner with management to scale the business, accelerate product development and expand the company's reach across workplace, government and clinical end markets.